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Background: Primary indicated prevention in individuals at-risk for psychosis has the
potential to improve the outcomes of this disorder. The ability to detect the majority
of at-risk individuals is the main barrier toward extending benefits for the lives of many
adolescents and young adults. Current detection strategies are highly inefficient. Only 5%
(standalone specialized early detection services) to 12% (youth mental health services)
of individuals who will develop a first psychotic disorder can be detected at the time
of their at-risk stage. To overcome these challenges a pragmatic, clinically-based,
individualized, transdiagnostic risk calculator has been developed to detect individuals
at-risk of psychosis in secondary mental health care at scale. This calculator has been
externally validated and has demonstrated good prognostic performance. However, it is
not known whether it can be used in the real world clinical routine. For example, clinicians
may not be willing to adhere to the recommendations made by the transdiagnostic risk
calculator. Implementation studies are needed to address pragmatic challenges relating
to the real world use of the transdiagnostic risk calculator. The aim of the current study
is to provide in-vitro and in-vivo feasibility data to support the implementation of the
transdiagnostic risk calculator in clinical routine.
Method: This is a study which comprises of two subsequent phases: an in-vitro phase
of 1 month and an in-vivo phase of 11 months. The in-vitro phase aims at developing
and integrating the transdiagnostic risk calculator in the local electronic health register
(primary outcome). The in-vivo phase aims at addressing the clinicians’ adherence to
the recommendations made by the transdiagnostic risk calculator (primary outcome)
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and other secondary feasibility parameters that are necessary to estimate the resources
needed for its implementation.
Discussion: This is the first implementation study for risk predictionmodels in individuals
at-risk for psychosis. Ultimately, successful implementation is the true measure of a
prediction model’s utility. Therefore, the overall translational deliverable of the current
study would be to extend the benefits of primary indicated prevention and improve
outcomes of first episode psychosis. This may produce significant social benefits for
many adolescents and young adults and their families.
Keywords: psychosis, schizophrenia, risk, transdiagnostic, prevention
INTRODUCTION
Outcomes of psychotic disorders are associated with high
personal, familial, societal, and clinical burden (1). There is thus
an urgent clinical and societal need for improving outcomes
of psychosis (1). The past two decades of clinical research
have opened new opportunities for ameliorating outcomes of
psychosis by intervening during its early clinical stages (1), in
individuals at Clinical High Risk for psychosis [CHR-P (2)] -
such as those meeting the At Risk Mental State criteria (3) or
other similar criteria (4)-. This type of intervention is termed
as “primary indicated prevention.” CHR-P individuals display
subtle symptoms and overall functional impairment (5) that are
due to the accumulation of several risk factors for psychosis (6, 7).
In the wake of these issues (8), they seek help at specialized CHR-
P clinics (9), where they receive a comprehensive psychometric
assessment in the context of a clinical interview (10). Overall,
the prognostic performance of this assessment is considered
to be good [except for their use as screening tools in the
general population (11, 12)] and comparable to that of similar
prognostic measurements that are employed in organic medicine
(13). Under those circumstances, CHR-P individuals have a
20% [see eTable 4 in (14)] probability of developing emerging
psychotic disorders [but not other non-psychotic disorders (15,
16)] over a relatively short period of 2 years. Primary indicated
prevention in CHR-P individuals has the unique potential to alter
the course of psychosis and reduce the duration of untreated
psychosis, although there is some uncertainty with respect to the
true effectiveness of available treatments (17–21). An additional
potential advantage is that secondary prevention in CHR-P who
will develop the disorder can reduce the duration of untreated
psychosis and ameliorate the severity of the disorder (1, 22).
As summarized in Figure 1, the potential real world impact of
the CHR-P paradigm for improving the outcomes of psychotic
disorders is determined by the successful and stepped integration
of the following key components:
(i) Efficient detection of individuals at-risk for psychosis;
(ii) Accurate prognosis of outcomes;
(iii) Effective preventive treatment.
As illustrated in Figure 1, the first rate-limiting step for
improving outcomes of psychosis through the CHR-P paradigm
is the detection of individuals who are at risk for psychosis. In
fact, even themost accurate prognostic tool and themost effective
preventive treatment would have little impact on improving the
outcomes of psychosis without proper scalability to the vast
majority of the at-risk population. Our lab (the Early Psychosis:
Intervention and Clinical-detection, EPIC) has investigated the
effectiveness of current detection strategies for identifying CHR-
P individuals for the first time. These strategies are largely based
on referrals to specialized CHR-P clinics (9) that are made
on suspicion of psychosis-risk (23). Our local National Health
Service (NHS) Trust, The South London And the Maudsley
(SLaM), in partnership with King’s College London and King’s
Health Partners, hosts one of the largest clinical services for
CHR-P individuals worldwide: the Outreach And Support In
South London (OASIS) (24). Established in 2001, the OASIS
has emerged as a reference point for psychosis prevention in
the UK and worldwide (24). The OASIS is detecting CHR-P
individuals from the community, primary care, and secondary
care through an extensive and ongoing outreach campaign,
which has been fully established over the past years. Despite
this outreach, we have found that OASIS’ detection strategies
are highly inefficient because only 5% of individuals diagnosed
with a first episode of non-organic ICD-10 psychosis in SLaM
had been detected at their CHR-P stage. This finding has
clear-cut clinical implications. For example, NHS England, in
April 2016 has implemented a new Access and Waiting Times-
Standard for Early Intervention in psychosis, which requires that
CHR-P are detected nationwide and treated rapidly (25, 26).
Although it is now an NHS requirement that all suspected
CHR-P patients who present to NHS Trusts are assessed and
interviewed for a psychosis-risk state (13), such an approach is
likely to miss the vast majority of those at risk. No alternatives are
on the horizon. Intensifying the inefficient outreach campaigns
currently adopted by CHR-P clinics is not viable because these
campaigns are idiosyncratic and unstandardized (23, 27, 28),
leading to a diluted transition risk and unreliable prognosis
(11, 12). Front-line youth mental health services such as the
Headspace initiative -as opposed to specialized CHR-P clinics
such as the OASIS- are also expected to detect more at-risk
individuals. Unfortunately, even youth mental health services
can detect only 12% of first episode cases at the time of their
CHR-P stage (29). It is thus clear that to extend the benefits of
the CHR-P paradigm some innovative approaches are urgently
needed (30).
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FIGURE 1 | Core clinical and research components for effective prevention of
psychosis.
To overcome these issues, we have developed a pragmatic,
clinically-based, individualized, transdiagnostic risk calculator
for the detection of individuals at risk of psychosis in secondary
mental health care at scale (24). In a subsequent step, the
calculator has been externally validated, demonstrating good
prognostic accuracy (24). Yet, a good model’s (external)
performance is necessary but not sufficient to ensure a clinical
use of a risk calculator. Implementation studies are first needed
to address pragmatic challenges relating to the use of a risk
calculator in clinical routine (31). These challenges may suggest
adaptations to the original models to allow its usability in the
real world. Ultimately, successful implementation is the true
measure of a prediction model’s utility (32). For example, the
transdiagnostic risk calculator was developed on retrospective
cohort data (24). As such, it is not known whether it can be
used prospectively in the real world of NHS Trusts. Data that
are necessary to run the calculator (age, gender, age by gender,
ethnicity, and ICD-10 index diagnosis) may not be available
or not accessible. Furthermore, clinicians’ adherence to the
recommendations made by the transdiagnostic risk calculator
is unknown. This represents the critical barrier toward its
scalability in clinical routine. We describe here the protocol for
the implementation study of this transdiagnostic risk calculator
in the NHS. To our best knowledge, this will be the first
implementation study of a risk calculator for clinical routine in
the CHR-P field.
The overall translational deliverable of the current study
would be to extend the benefits of primary indicated prevention
and improve outcomes of first episode psychosis. This, in turn,
may produce significant social benefits and cost-saving to many
adolescents and young adults, their families and the NHS.
METHODS
This is a feasibility study which will evaluate essential real world
parameters associated with the implementation of an electronic,
clinically-based, individualized, transdiagnostic risk calculator
for the detection of individuals at risk and the prediction of
psychosis in secondary mental health care. Obtaining these
figures is a necessary step in order to accurately estimate the
resources (e.g., staffing) needed for the routine clinical use of
the calculator. There are two phases in this study: an initial in-
vitro (1 month) testing which does not involve patients contact
and a second in-vivo piloting (11 months, total study duration 12
months), which involves recruitment of SLaM patients. Before
we present the study design, we will briefly summarize the core
characteristics of the transdiagnostic risk calculator.
Clinically-Based, Individualized,
Transdiagnostic Risk Calculator for the
Automatic Detection of Individuals at Risk
of Psychosis in Secondary Mental
Health Care
In a previous meta-analysis, we showed that secondary mental
health care is the most frequent source of referrals to CHR-
P services such as the OASIS (23). We additionally confirmed
that the recruitment of individuals for CHR-P assessment
through secondary mental health services is associated with the
highest probability of developing psychosis (27). In fact, these
individuals are more likely to have accumulated several risk
factors for psychosis such as affective comorbidities, substance
abuse and social deprivation (6). These findings are concurrent
to the European Psychiatric Association guidelines, which
recommend that CHR-P assessment should only be offered to
individuals who are “already distressed by mental problems and
seeking help for them” (33). The transdiagnostic risk calculator
presented here is therefore in line with the clinical guidelines in
the field.
Our calculator was developed and externally validated in
a large clinical dataset of non-psychotic patients affected with
non-organic mental disorders (n = 91,199), in the National
Institute of Health Research (NIHR) Maudsley Biomedical
Research Centre (BRC) Case Register. This register is electronic,
because SLaM is paper-free, and all clinicians record their activity
electronically on the Patient Journey System (PJS), as part of
their clinical routine. PJS is a comprehensive record of all clinical
information recorded throughout patients’ journeys through
SLaM NHS Trust services, including demographic and contact
information, dates and other details of referrals and transfers,
detailed clinical assessments, care plans and medication, clinical
activity, and reviews. Anonymised information from PJS is
subsequently used to create the Clinical Record Interactive
Search (CRIS). CRIS allows researchers to search from PJS
records. The details of the CRIS and the local electronic health
record have been published previously (34–36). Therefore, this
calculator leverages the potentials of e-Health innovations.
The original study followed state-of-the-art guidelines for
model development and validation (37). Thus, the external
validation was done through a geographical split of the initial
database in a derivation (Lambeth and Southwark SLaM
boroughs, n = 33,820) and validation (Lewisham and Croydon
SLaM boroughs, n = 54,716). The calculator showed good
prognostic accuracy in the external validation, in terms of
overall performance (R2 = 0.72), discrimination (Harrell’s
C = 0.79) and calibration (calibration slope = 0.96) (24). Our
calculator is based on simple sociodemographic variables (age,
gender, ethnicity, age by gender interaction and ICD-10 index
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FIGURE 2 | Example of outcomes produced by the transdiagnostic risk calculator that is under implementation in the current study.
diagnosis) that can be easily accessed in clinical practice. It has
been termed as “transdiagnostic” because it leverages several
ICD-10 index diagnoses, and it can detect risk of psychosis
across all diagnostic spectra (i.e., acute and transient psychotic
disorders, substance abuse disorders, bipolar mood disorders,
non-bipolar mood disorders, anxiety disorders, personality
disorders, developmental disorders, childhood/adolescence onset
disorders, physiological syndromes andmental retardation). This
also represents one of the broadest transdiagnostic studies in
psychiatry overall (38). The selection of predictors that were
available in the local electronic health records was deliberately
done with the view of facilitating its implementation in
clinical routine at scale, which is an essential prerequisite to
improve the detection of individuals at risk of psychosis. The
predictors were preselected on the basis of a priori meta-
analytical knowledge (39), a method which is recommended to
develop robust prognostic models (31). In fact, the calculator
is characterized by a significant clinical utility (net benefits)
within a 1–50% range of threshold probability (individuals risk
of developing psychosis by 5 years) (24). Such a range of
predicted risk for psychosis is clinically meaningful since it is
unlikely that a calculator would be needed to guide clinical
practice for individuals with higher or lower predicted risks.
The transdiagnostic risk calculator has also been implemented
online (www.psychosis-risk.net) (24). This would allow its use
in NHS Trusts that do not routinely employ electronic health
records. An example of the output that is provided by the
transdiagnostic risk calculator is appended in Figure 2. The core
characteristics of the transdiagnostic risk calculator are appended
in Table 1.
TABLE 1 | Core characteristics of the transdiagnostic risk calculator.
Robust It includes predictors that have been selected through a priori
clinical knowledge
Pragmatic It is agnostic with respect to etiopathology of psychosis
Cheap It leverages predictors that are routinely collected by clinicians
Automatized It can accommodate electronic health records as well as the
manual entry of predictors
e-Health It has been implemented online
Scalable It can be used to screen large electronic health records
Optimisable It can be further refined by the inclusion of other predictors
Design
In-vitro Phase
The initial phase will have the transdiagnostic risk calculator
integrated into the local electronic health register (step
0, Figure 3). This will involve several activities such as
developing the prototype, addressing in-vitro feasibility problems
associated with its implementation in SLaM clinical practice, and
conducting clinician engagement work prior to initiating the in-
vivo piloting. The team has already started initial work to prepare
the implementation of the calculator. Firstly, we have approached
the local NHS Trust IT facility (SL@M Connect) to discuss
governance issues for using clinical material from the local NHS
Trust. SL@MConnect has endorsed our study and will support it.
Secondly, we have conducted data quality checks with the CRIS
team to ensure that the resources needed are in place. Thirdly
we have started the in-vitro phase by extracting preliminary data
and running our calculator. We have also collaborated with the
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Center for Translational Informatics in order to fully implement
the calculator in the local electronic health register. Anonymised
data will be used during this phase to develop a prototype of
the tool that can be automatised within the local electronic
health register. Qualitative data will be collected to identify
pragmatic barriers associated with the use of the transdiagnostic
risk calculator. This will be collected through organizing two
workshops, each composed of five SLaM clinicians. This phase
would also tune the pilot threshold probability to be used in
the next phase and address implementation challenges that have
emerged from the in-vitro phase. This phase will be developed
in collaboration with SLaM IT Connect and with the Center
for Translational Informatics at the Institute of Psychiatry,
Psychology, and Neuroscience. Approval for the in-vitro study
was granted by the Oxfordshire Research Ethics Committee
C. Because the data set is made up of de-identified data,
informed consent is not required. Furthermore, during this phase
we will try to complete a further external validation of the
transdiagnostic risk calculator in an independent NHS Trust in
the UK which is using CRIS. This is seen as an essential step to
address the transportability of our transdiagnostic risk calculator
across different clinical scenarios.
The in-vitro phase will last 1 month.
In-vivo Phase
This phase will consist of a prospective feasibility study to test the
real world usability of the transdiagnostic risk calculator to detect
individuals at risk of psychosis at scale in clinical routine.
During this phase, a prototype will be made freely available
to clinicians working in secondary mental health teams. In
practice, clinicians will not be required to enter any new variables
because all the predictors are already available as part of the
standard clinical practice. In the first step (see step 1, Flow chart),
the research team will screen potential patients meeting our
study criteria using de-anonymised electronic health register data
(CRIS). The data for these patients will be accessed by the study
team to screen potential participants with the transdiagnostic
risk calculator. The electronic health register will also be used
to identify the responsible clinician for any individuals who are
at risk as determined by the pre-defined threshold (established
during the in-vitro phase).
The research team will then contact the responsible clinician
through manual alerts (e.g., emails) and phone contact,
recommending the patient be referred for a refined psychosis
assessment. If an individual does not reach the threshold, the
calculator will recommend no further assessment and standard
care will be offered as usual. If possible, these alerts will be
automatised during the study. During the second step (step 2,
Flow Chart), the responsible clinicians will then decide whether
to initiate the referral or not. A crucial outcome to be investigated
will be the impact of different types of alerts on the clinicians’
adherence on the use of the transdiagnostic risk calculator. If the
individual is not referred for further assessment, standard care
will be offered as usual. In the case the participant is referred
for further assessment, the clinician will ask the patient if they
consent to their details being given to the research team. If they
do, the individual will be contacted by the research team and the
procedure for collecting informed consent will be initiated.
If the patient agrees to participate in the study, they will then
be invited to undergo a refined assessment (step 3, Flow Chart),
which includes the standard CHR-P assessment. Specifically, we
will use the combined Comprehensive Assessment for At Risk
Mental States (CAARMS, version 12/2006) (3) and Structured
Interview for Prodromal-Risk Syndromes, version 5.0 (SIPS)
(40), clinician-rated and iPad version, that have been developed
in our department as part of previous ongoing studies.
At the end of this assessment, the researchers would
communicate the results to the responsible clinicians (step 4,
Flow Chart). In case the individuals would meet the standard
intake criteria for a state of risk for psychosis (i.e., a CHR-P
state), they would be referred to the local Clinical High Risk
service [the OASIS (9)] for standard care as recommended by
the NICE (41). If the individuals do not meet the intake criteria
for a CHR-P state, the referrer will be informed, and standard
care provided accordingly. Overall, there will be no change in the
current standard care for any participants. This prototype will be
piloted in all local secondary mental health services present in the
borough of Lambeth, Lewisham, Croydon and Southwark.
Participants will be reimbursed for their participation in the
study at an hourly rate of £10. For patients under the age of 16,
their time will be reimbursed with Amazon gift vouchers, again
to the value of an hourly rate of £10 per hour. Table 2 lists the
study procedures.
The in-vivo phase will last 11 months.
Follow-Up
Individuals who are selected through the transdiagnostic risk
calculator, referred by their clinicians for a psychosis-risk
assessment and who accept it will be invited again to a face-to-
face clinical follow-up at 6 months. This will consist of the same
measures acquired at baseline.
Statistics
Sample Size
This is a feasibility study to investigate key implementation
parameters for an electronic risk calculator. As such the study
is neither designed nor powered to validate new tools or test
specific hypotheses.
The primary outcome of the in-vitro phase is the development
and integration of the transdiagnostic risk calculator in the local
electronic health register. As such, no power calculation is made
for the in-vitro primary outcome.
They key rate-limiting barrier toward a scalable use of the
transdiagnostic risk calculator in the broader clinical scenario
is the clinicians’ adherence to the recommendations made
by the calculator itself. Therefore, the primary outcome of
the in-vivo phase of this study is the adherence of clinicians
to the use of the calculator, defined by the proportion of
clinicians who have responded to the prompts sent on the
recommendation of the electronic risk calculator from SLaM
secondary mental health care. The sample size calculation is
therefore made for this primary outcome. In line with the
NIHR guidance, our main outcomes are feasibility parameters,
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FIGURE 3 | Flow chart of study design including the in-vitro and in-vivo phase.
and sample size calculation is made for the expected level of
precision (45). Assuming a predicted psychosis threshold of
5–10% (at 2 years), on the basis of the previous study (24),
we expect to detect at least 120 at-risk individuals per 11
months recruitment in SLaM. Conservatively assuming that
only half of SLaM clinicians would eventually respond to
the alerts generated by the calculator, the anticipated sample
size would allow us to have an acceptable (42) maximum
margin of error of 0.1 (i.e., 95%confidence interval (CI)
±0.1) for adherence rates of clinicians >60%. The secondary
outcomes of the in-vivo phase will measure other key feasibility
parameters that are necessary to implement the calculator in
the wider clinical routine: impact of different types of alerts
on the clinicians’ adherence to the recommendations made
by the transdiagnostic risk calculator; raw number of referrals
initiated from secondary mental health care clinicians for an
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TABLE 2 | Study procedures for individuals detected by the transdiagnostic risk
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assessment of psychosis-risk; qualitative reasons for any lack of
clinicians’ adherence.
Analysis
This is a feasibility study and it is not planned to test any statistical
hypotheses with regard to any of the endpoints in a confirmatory
sense. For the exploratory evaluation of our hypotheses, a two-
sided 95% CI of adjusted treatment differences will be computed.
However, the CIs will have to be interpreted in the perspective
of the exploratory character of study, i.e., as an interval estimate
for effects under these conditions. All statistical analyses will be
performed using STATA version 14 (43).
Participants
Inclusion Criteria
• Subject receiving any first ICD-10 diagnosis of non-psychotic
mental disorder (including Acute and Transient Psychotic
Disorders) at SLaM (borough of Lambeth) between April 1st
2018 and March 28th 2018;
• Aged ≥14;
• Subject with a good understanding of spoken and
written English.
Exclusion Criteria
• Present or past diagnosis of any ICD-10 psychotic disorder
[excluding Acute and Transient Psychotic Disorders (44)];
• Any evidence of organic condition that may be responsible for
psychotic symptoms.
Withdrawal of Subjects
If an individual decides to take part in the study, they will still
be free to withdraw at any time, without giving a reason. Their
decision will not affect the standard of care they receive from any
medical services at any time. Identifiable data already collected
with consent would be retained and used in the study. No further




• Primary outcome: to develop and integrate an automated
transdiagnostic risk calculator into the local electronic
health register;
• Secondary outcome: to externally validate the transdiagnostic
risk calculator in an independent NHS Trust in the UK;
In-vivo Phase
• Primary outcome: adherence of clinicians to the use of the
transdiagnostic risk calculator (proportion of clinicians who
have responded to the prompts sent on the recommendation
of the transdiagnostic risk calculator).
• Secondary outcome: impact of different types of alerts on the
clinicians’ adherence to the recommendations made by the
transdiagnostic risk calculator.
• Secondary outcome: raw number of referrals initiated from
secondary mental health care clinicians for an assessment
of psychosis-risk.




This is not a randomized clinical trial but instead a prospective
cohort study. The in-vitro stage utilizes de-anonymised data
from the local electronic case register, while the second uses a
case-control design (prospective cohort study in SLaM).
Types of Data
The main experimental outcomes are quantitative and include
the raw number of at risk cases detected by the calculator, the
raw number of referrals made by clinicians, the raw number
of individuals meeting CHR-P criteria, the raw number of
individuals developing any ICD-10 psychotic disorder over time.
Qualitative data will also be acquired from workshops conducted
with SLaM clinicians during the in-vitro phase and from SLaM
clinicians contacted during the in-vivo phase (in case of lack
of adherence).
Format and Scale of Data
Data will be stored in standard formats using standard software
for the field allowing easy sharing with other scientists as well as
maintaining long-term validity.
Data Access
Data will only be accessed by the research team. Physical data
will be stored in a locked drawer at OASIS with access restricted
to the research team. Information collected from participants
during the clinical investigation will be treated confidentially.
The researchers will collect data and transfer it without recording
the patient’s name or date of birth but coded with a subject
identification code. Therefore, data is not directly traceable to
individual subjects. A subject identification code links the data
to the individual subject. The code will be safeguarded by the
responsible investigator at the site; the key to this code (subject
identification code list) will be kept at the site, with limited access
by study team members only.
Data Security
Privacy laws and regulations will be adhered to during all
procedures related to this study. The collection and processing
of participants’ personal information will be limited to what
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is necessary to ensure the study’s scientific practicability
and to assess the research questions. Information collected
from participants during this clinical investigation will be
treated confidentially.
The researchers collecting the data for this study will work
under the direct supervision of the consultant psychiatrist of the
OASIS team (Paolo Fusar-Poli) and who will ensure there is no
breach of confidentiality.
Once recruited to the research, the participants will be
allocated a participant ID number which will be attached to
all research documentation along with their initials and date
of participation. Any documentation, which would allow the
identification of personal data, will be collected under the
participant ID and will only be accessible by the researchers.
All information collected during the study will be stored in a
secure location at OASIS within a locked drawer only accessible
by the researcher and the OASIS team. All data collected from
the baseline assessment will be anonymised using participant ID
and stored on a secure, encrypted, password-protected server.
iPads will be based on existing technologies developed at King’s
College London and are in use for other research projects at the
Department of Psychosis Studies.
Research data will be stored for a minimum of 5 years
following the completion of the study. We intend to make use
of the King’s College London (KCL) Research Data Management
system where data can be stored long-term.
Ethics and Regulatory Approval
The Chief Investigator of this study undertakes to abide by the
ethical principles underlying the Declaration of Helsinki and
good practice guidelines on the proper conduct of research.
If the research is approved the Chief Investigator undertakes
to adhere to the study protocol, the terms of the full application
as approved and any conditions set out by review bodies in giving
approval. The Chief Investigator undertakes to notify review
bodies of substantial amendments to the protocol or the terms
of the approved applications and to seek a favorable opinion from
themain Research Ethics Committee (REC) before implementing
the amendment. The Chief Investigator undertakes to submit
annual progress reports setting out the progress of the research,
as required by review bodies.
The CI will ensure that REC Favorable Opinion, Health
Research Authority (HRA) approval, and SLaM Confirmation of
Capacity and Capability will be in place before recruiting from
SLaM. Should it be necessary to add research sites at a later
stage, the sponsor will be approached to review an amendment
for submission to the HRA, and Confirmation of Capacity and
Capability will be obtained from the new NHS sites before
starting recruitment from research sites.
Consent Procedures in Minors
For potential participants who are under the age of 16 years old
at the start of the study, informed consent should be provided by
their legal representatives/parents, in line with the Declaration
of Helsinki and International Conference on Harmonization-
GoodClinical Practice (ICH-GCP). Their consentmust represent
the minor’s presumed will and may be revoked at any time,
without detriment to the minor. Whenever appropriate, the
minor should participate in the informed consent process
together with the parents. If the minor is deemed to be able
to give assent to decisions about participation in research, the
researcher will obtain this assent in addition to the consent
of the legal representatives/parents. If the minor’s assent is
not obtained, it is recommended that this is documented with
justification in the consent form which is signed by the legal
representatives/parents and investigator. The minor’s assent is
not sufficient to allow participation in the study; informed
consent of the legal representatives/parents is required. Consent
from legal representatives/parents and assent from the minor
should be sought at the same time. In any case, the minor will
receive information according to its capacity of understanding
regarding the study and its risks and benefits from staff with
experience in minors. The explicit wish of a minor who is capable
of forming an opinion and assessing this information to refuse
participation will be followed; in such case, the minor can be
withdrawn from the study at any time.
In case a minor reaches adulthood (age of 16) during the
study, the researcher is obliged to obtain informed consent from
this participant as soon as possible. Informed consent from
legal representative/parents is no longer required, although it is
recognized that an adolescent is still vulnerable and may require
additional discussions and explanations.
In case the above-described procedures are not in line with
any applicable local law or regulation, any deviations need to
be discussed and agreed upon with the sponsor, as well as
clearly documented.
If a minor or incapacitated subject does not want to
participate, they will not be included in the study. This is also
explicitly stated in the information letter.
Management of Disclosures and Distress
The content of the assessments can potentially lead to patients
feeling distressed or disclosing sensitive information. There are
guidelines in place for managing these incidents. If this occurs,
the researcher will contact the patient’s consultant or team
manager to inform them. The responsible clinician will then offer
the patient an assessment and treatment plan. For issues where
the consequences are more imminent, the Accident & Emergency
department at King’s College Hospital will be contacted and
appropriate treatment and support will be offered.
Quality Assurance, Data Handling, Publication Policy,
and Finance
Names and contact details of participants will be kept on separate
databases from experimental data, with anonymous subject codes
referencing between the two. Data will be kept in accordance
with study ethical approval, research governance and the Data
Protection Regulation Act (2018). We will encourage access to
the anonymised raw data by external collaborators within this
framework, in accordance with the international policy on data
preservation and sharing, while maintaining strict confidentiality
for study participants. Encrypted data will be saved for long-term
storage and sharing within the KCL infrastructure.
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The Institute of Psychiatrym Psychology and Neuroscience
(IoPPN) has a dedicated communications office which
disseminates research findings via the media (press releases,
expert comment proactive placing) and communications
vehicles such as the King’s website, and those of partner
organisations such as SLaM NHS Foundation trust and other
King’s Health Partners.
The study has been externally reviewed and approved for
funding by King’s Health Partners.
DISCUSSION
We have presented an innovative implementation study
protocol, applying a pragmatic, clinically-based, individualized,
transdiagnostic, risk calculator to the NHS. To our best
knowledge, this is the first implementation study of a
risk calculator for clinical routine in the CHR-P field.
Implementation studies are as scarce as essential (31). The
proliferation of risk models in the CHR-P field as well as in
psychiatry has occurred largely without appropriate attention to
implementation challenges, resulting in many models that have
little or no clinical impact (32). In fact, manymore risk prediction
models are published than are externally validated, and only a
tiny minority of these is then implemented in the NHS (31). To
achieve successful implementation, which is the true measure of
a prediction model’s utility, we considered that the end from the
beginning of the model development process. Because our aim
was to improve the detection of individuals at risk of psychosis,
it was necessary to screen a large NHS Trust at scale. To achieve
this goal, we selected predictors that were already collected by
clinicians as part of their clinical routine. Furthermore, the
requirement of simple variables for implementation increases the
number of data sets that could be used for the external validation
of existing models, a current gap in the implementation of risk
prediction models in psychiatry. Because of these considerations,
we believe that the study protocol here described can advance
knowledge and foster translational precision psychiatry research.
We hope that the pragmatic and operational nature of this
protocol will guide future researchers, funders and ethics
committees toward the development of implementation studies
for psychiatric populations. We recommend this protocol as a
starting point to guide future implementation studies for risk
prediction models in populations at risk for psychosis.
We believe that the protocol described here can contribute
to the development of solid risk prediction models that can be
implemented in clinical routine.
STUDY STATUS
The study status is ongoing, and recruitment for the in-vivo
phase commenced on 1 August 2018. The study has been
approved by National Research Ethics Service (NRES) East of
England - Cambridgeshire and Hertfordshire Research Ethics
Committee (Ref: 18/EE/0066).
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